ArticleCytoskeleton (Hoboken, N.J.)2025
Pharmacological Inhibition of β Myosin II Disrupts Sarcomere Assembly in Human iPSC-Derived Cardiac Myocytes.
Article in Cytoskeleton (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological Inhibition of β Myosin II Disrupts Sarcomere Assembly in Human iPSC-Derived Cardiac Myocytes.Cytoskeleton (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Sarcomeres are the fundamental contractile units of striated muscle. The functional roles of the cardiac-specific myosin heavy chains, MYH6 (α myosin II) and MYH7 (β myosin II) during sarcomere assembly remain controversial. To address this, we utilized a selective MYH7 inhibitor, mavacamten, in combination with siRNA-mediated knockdown of MYH6 or MYH7 in human induced pluripotent stem cell-derived cardiomyocytes (hiCMs). Our results demonstrate that sarcomere assembly proceeds when either MYH6 or MYH7 is independently depleted, suggesting functional redundancy. However, pharmacological inhibition of MYH7 contractility by mavacamten disrupts sarcomere assembly in a concentration-dependent manner. Sensitivity to mavacamten correlated with the relative abundance of MYH6 and MYH7: sarcomere assembly by MYH7-enriched (i.e., MYH6-depleted) hiCMs was more sensitive to mavacamten (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.